Summary & Overview
HCPCS S9559: Home Injectable Interferon Therapy, Per Diem
HCPCS Level II code S9559 represents a per diem billing code for home injectable therapy involving interferon, encompassing administrative functions, professional pharmacy services, care coordination, and all necessary supplies and equipment. This code is relevant nationally for payers and providers managing outpatient biologic therapies delivered in the home setting, where drugs and nursing visits are reported separately. It matters because home-based biologic administration shifts site-of-service utilization and creates distinct billing and care coordination workflows compared with facility-based infusion.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how S9559 is used in practice, typical sites of service, and which elements are bundled versus billed separately. The publication outlines benchmarks and reimbursement context, summarizes relevant policy considerations affecting home infusion and pharmacy-administered biologics, and situates the code within clinical care pathways for conditions treated with interferon. Data limitations are identified where input fields were not provided.
This summary is designed for payers, provider billing staff, pharmacy services, and policy analysts seeking a national-level understanding of HCPCS Level II code S9559 and its role in home-based injectable interferon therapy.
Billing Code Overview
HCPCS Level II code S9559 describes home injectable therapy for interferon, provided on a per diem basis. The code covers administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment associated with home administration. Drugs and nursing visits are billed separately and are not included in the S9559 per diem.
Service type: Home-based pharmaceutical administration and care coordination
Typical site of service: Patient home (home health/home infusion setting)
Clinical & Coding Specifications
Clinical Context
A home-based adult patient with relapsing-remitting multiple sclerosis is prescribed interferon beta therapy delivered via subcutaneous injection at home. The patient receives a per‑diem administrative service that covers medication management coordination, professional pharmacy services (education, adherence assessment), scheduling and oversight of nursing visits for injection instruction or observation, and provision of necessary disposables (syringes, sharps container, alcohol swabs). The clinical workflow begins with the prescriber writing the interferon order and documenting indication and dosing. The pharmacy or home infusion provider establishes prior authorization with the payer, performs patient education on self-injection technique, documents baseline adverse effect counseling, and arranges nursing visits when needed (initial home visit for teaching, periodic competency checks, and symptom monitoring). Clinical monitoring includes assessment of flu-like symptoms, injection site reactions, routine laboratory monitoring (CBC, liver function tests) per the prescriber’s protocol, and communication of abnormal results to the ordering clinician. Visits are coordinated with the drug and nursing claims: the per‑diem administrative code S9559 is billed for the ongoing home injectable therapy administrative services while the interferon drug and any nursing visit CPT/HCPCS are billed separately. Typical site of service is the patient’s residence (home health / home infusion setting). Typical payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA plans, and Medicare, each requiring documentation of medical necessity, prior authorization when applicable, and clear linkage between S9559 and the separately billed drug and nursing services.
Coding Specifications
| Modifier | Description |
|---|